Preliminary observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia.
- Author:
Yao-zhong ZHAO
1
;
Hong-qiang LI
;
Da-peng LI
;
Rui LI
;
Jun-yuan QI
;
Chang-chun WAN
;
Chun-lin ZHOU
;
Zhi-qiang WANG
;
Lin-sheng QIAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Arsenicals; administration & dosage; adverse effects; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; drug therapy; Male; Middle Aged; Oxides; administration & dosage; adverse effects; Remission Induction; Treatment Outcome; Tretinoin; administration & dosage; adverse effects
- From: Chinese Journal of Hematology 2003;24(1):32-34
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the efficacy and side effect of the all-trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)) combination in acute promyelocytic leukemia (APL).
METHODSTwenty APL patients were treated with the ATRA and As(2)O(3) combination, and 18 of them could be evaluated. The treatment protocol was as following: 10 mg As(2)O(3) (0.1% solution) in 500 ml 50 g/L glucose solution for intravenous drip over 4 to 6 hours once a day, ATRA was given 25 mg/m(2) every day.
RESULTSSeventeen of the 18 patients achieved complete remission (CR), the CR rate was 94.4%. All 14 newly diagnosed patients and 3 of 4 relapsed patients achieved CR. No significant side effect was observed.
CONCLUSIONThe As(2)O(3) and ATRA in the treatment of APL can obtain a higher CR rate and a shorter duration for achieving CR.
